Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Avatrombopag in Thrombocytopenia After Haplo-HSCT
NCT06202625Phase 3Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- May 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Thrombocytopenia comparing Avatrombopag with Placebo (2 arms). Primary endpoint: Proportion of Complete Response at Day 60. Started May 2024; status: recruiting.
02
Drugs
avatrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT06202625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06202625.